Drugs / Ornithine Phenylacetate
Ornithine Phenylacetate
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03846843 | Aug 2016 → Nov 2017 | cirrhosis of liver | Ocera Therapeutics | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT01548690 | Jun 2012 → Feb 2017 | acute liver failure | William Lee | Completed | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT01434108 | Oct 2011 → Mar 2015 | cirrhosis of liver | Hospital Universitari Vall d'Hebron Research Institute | Completed | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT01634230 | — | acute liver failure | Ocera Therapeutics | No longer available | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT01966419 Comparator | Jan 2014 → Dec 2016 | hepatic encephalopathy | Ocera Therapeutics | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ornithine-phenylacetate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01434108 ↗ |
| Known as | L-ornithine phenylacetate | “BACKGROUND AND OBJECTIVE: L-Ornithine phenylacetate is an intravenous formulation of the L-ornithine salt of phenylacetic acid under development for the treatment of hepatic...” PMID 34786649 ↗ Nov 2021 |
| Known as | OCR-002 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01634230 ↗ |
| Route | Intravenous | “administered as a continuous i.v. infusion for 24 hours” NCT01434108 ↗ |